However, OLA1P2 was not found to serve as a key mediator of aspirin treatment in esophageal cancer, liver cancer, or pancreatic cancer, although clinical trials have indicated that aspirin significantly reduces the risks of these cancers [22–24]. This evidence concerns the gene OLA1P2 and cancer.